SC

Serrado Capital

North America, New York, United States, New York

Description

Public Market Healthcare Investment Firm

Investor Profile

Serrado Capital has made 4 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

  • Post Ipo Equity (75%)
  • Series B (25%)

Country Focus

  • United States (75%)
  • Denmark (25%)

Industry Focus

  • Biotechnology
  • Health Care
  • Oncology
  • Biopharma
  • Pharmaceutical
  • Therapeutics
  • Medical
  • Life Science
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Serrado Capital frequently co-invest with?

Ridgeback Capital
North America, New York, United States, New York
Co-Investments: 1
Sectoral Asset Management
North America, Quebec, Canada, Montréal
Co-Investments: 1
Samsara BioCapital
North America, California, United States, Palo Alto
Co-Investments: 2
aMoon Fund
Asia, HaMerkaz, Israel, Ra'anana
Co-Investments: 1
Biotechnology Value Fund
North America, California, United States, San Francisco
Co-Investments: 3
LV
North America, New York, United States, New York
Co-Investments: 1
Avoro Capital Advisors
North America, New York, United States, New York
Co-Investments: 2
Vivo Capital
North America, California, United States, Palo Alto
Co-Investments: 3
Logos Capital
North America, California, United States, San Francisco
Co-Investments: 2
Janus Henderson Investors
Europe, England, United Kingdom, London
Co-Investments: 1

What are some of recent deals done by Serrado Capital?

Delcath Systems

New York, New York, United States

Delcath Systems is an interventional oncology company that focuses on the treatment of metastatic liver cancer.

BiotechnologyHealth CareOncologyPharmaceutical
Post Ipo EquityMar 27, 2023
Amount Raised: $85,000,000
Aadi Bioscience

Pacific Palisades, California, United States

Aadi Bioscience develops a potentially mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases.

BiopharmaBiotechnologyLife ScienceOncology
Post Ipo EquityAug 26, 2021
Amount Raised: $154,999,876
Viracta Therapeutics

Cardiff By The Sea, California, United States

Viracta Therapeutics is a precision oncology company focused on new treatment of virus-associated malignancies.

BiopharmaBiotechnologyHealth CareMedicalOncologyPharmaceuticalTherapeutics
Post Ipo EquityFeb 24, 2021
Amount Raised: $65,000,000
IO Biotech

Copenhagen, Hovedstaden, Denmark

IO Biotech is a clinical-stage biotech company developing disruptive immune therapies for the treatment of cancer.

BiotechnologyHealth CareTherapeutics
Series BJan 13, 2021
Amount Raised: $154,457,623